BMRN vs GNLX · P/E 40, rev $1.76B vs rev $8.0K
Biomarin Pharmaceutical Inc (BMRN) versus Genelux Corporation Common Stock (GNLX) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Genelux Corporation Common Stock (GNLX) is a biotechnology company listed on US.
Latest reported BMRN revenue for 2026-06-30 was $1.76B. Net income was $150.3M. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported GNLX revenue for 2025-12-31 was $8.0K. Net income was -$32.1M. Revenue was up 0.0% from 2024-12-31 to 2025-12-31. GNLX currently screens at market cap $130.6M.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. GNLX currently screens at market cap $130.6M.
Not investment advice. Open the BMRN and GNLX stock pages for the full models.
Not investment advice.